Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 15, Number 5—May 2009

Research

CTX-M β-Lactamases in Escherichia coli from Community-acquired Urinary Tract Infections, Cambodia

Etienne RuppéComments to Author , Sopheak Hem, Sovannarith Lath, Valérie Gautier, Frédéric Ariey, Jean-Louis Sarthou, Didier Monchy, and Guillaume Arlet
Author affiliations: Institut Pasteur du Cambodge, Phnom Penh, Cambodia (E. Ruppé, S. Hem, S. Lath, F. Ariey, J.-L. Sarthou, D. Monchy); Université Pierre et Marie Curie-Paris Faculté de Médecine, Paris, France (V. Gautier, G. Arlet); Assistance Publique-Hôpitaux de Paris–Hôpital Tenon, Paris (V. Gautier, G. Arlet)

Main Article

Table 2

Resistance to antimicrobial agents among ESBL-positive and ESBL-negative Escherichia coli, Cambodia, 2004–2005*

Antimicrobial agent Resistance ratios, % (no. resistant strains)
p value
ESBL+, n = 34 ESBL–, n = 59 Total, n = 93
Fluoroquinolones 94 (32) 53 (31) 68 (63) <0.001
Cotrimoxazole 85 (29) 69 (41) 75 (70) 0.06
Aminoglycosides 65 (22) 27 (16) 42 (39) <0.01
Co-amoxiclav 94 (32) 19 (11) 46 (43) <0.001
Cefoxitin 41 (13) 11 (7) 22 (20) <0.001
Nitrofurantoin 0 0 0 NS
Fosfomycin 0 0 0 NS

*ESBL, extended-spectrum β-lactamase; NS, not significant.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO